FAP-DR5

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameFAP-DR5
Drug Alias NameRG-7386RO-6874813
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionFibroblast activation protein alpha antagonistsTumor necrosis factor receptor superfamily member 10B agonists
TargetsTumor necrosis factor receptor superfamily member 10BProlyl endopeptidase FAP
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesFranceSpain
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMillennium Pharmaceuticals IncF. Hoffmann-La Roche Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesF. Hoffmann-La Roche Ltd
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A